Literature DB >> 12176897

B cells immortalized by a mini-Epstein-Barr virus encoding a foreign antigen efficiently reactivate specific cytotoxic T cells.

Andreas Moosmann1, Naeem Khan, Mark Cobbold, Caroline Zentz, Henri-Jacques Delecluse, Gabi Hollweck, Andrew D Hislop, Neil W Blake, Debbie Croom-Carter, Barbara Wollenberg, Paul A H Moss, Reinhard Zeidler, Alan B Rickinson, Wolfgang Hammerschmidt.   

Abstract

Lymphoblastoid cell lines (LCLs) are human B cells latently infected and immortalized by Epstein-Barr virus (EBV). Presenting viral antigens, they efficiently induce EBV-specific T-cell responses in vitro. Analogous ways to generate T-cell cultures specific for other antigens of interest are highly desirable. Previously, we constructed a mini-EBV plasmid that consists of less than half the EBV genome, is unable to cause virus production, but still immortalizes B cells in vitro. Mini-EBV-immortalized B-cell lines (mini-LCLs) are efficiently produced by infection of B cells with viruslike particles carrying only mini-EBV DNA. Mini-EBV plasmids can be engineered to express an additional gene in immortalized B cells. Here we present a mini-EBV coding for a potent CD8(+) T-cell antigen, the matrix phosphoprotein pp65 of human cytomegalovirus (CMV). By means of this pp65 mini-EBV, pp65-expressing mini-LCLs could be readily established from healthy donors in a one-step procedure. We used these pp65 mini-LCLs to reactivate and expand effector T cells from autologous peripheral blood cells in vitro. When generated from cytomegalovirus (CMV)-seropositive donors, these effector T-cell cultures displayed strong pp65-specific HLA-restricted cytotoxicity. A large fraction of CD8(+) T cells with pp65 epitope specificity was present in such cultures, as demonstrated by direct staining with HLA/peptide tetramers. We conclude that the pp65 mini-EBV is an attractive tool for CMV-specific adoptive immunotherapy. Mini-EBVs could also facilitate the generation of T cells specific for various other antigens of interest.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12176897

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  24 in total

1.  Epstein-Barr virus BNRF1 protein allows efficient transfer from the endosomal compartment to the nucleus of primary B lymphocytes.

Authors:  R Feederle; B Neuhierl; G Baldwin; H Bannert; B Hub; J Mautner; U Behrends; H J Delecluse
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

2.  Visualization of antigen-specific human cytotoxic T lymphocytes labeled with superparamagnetic iron-oxide particles.

Authors:  Ambros J Beer; Konstantin Holzapfel; Juliana Neudorfer; Guido Piontek; Marcus Settles; Holger Krönig; Christian Peschel; Jürgen Schlegel; Ernst J Rummeny; Helga Bernhard
Journal:  Eur Radiol       Date:  2008-02-20       Impact factor: 5.315

3.  Primary B-cell infection with a deltaBALF4 Epstein-Barr virus comes to a halt in the endosomal compartment yet still elicits a potent CD4-positive cytotoxic T-cell response.

Authors:  Bernhard Neuhierl; Regina Feederle; Dinesh Adhikary; Birgit Hub; Karsten Geletneky; Josef Mautner; Henri-Jacques Delecluse
Journal:  J Virol       Date:  2009-02-25       Impact factor: 5.103

Review 4.  Herpesviral vectors and their application in oncolytic therapy, vaccination, and gene transfer.

Authors:  Susanne M Bailer; Christina Funk; André Riedl; Zsolt Ruzsics
Journal:  Virus Genes       Date:  2017-06-20       Impact factor: 2.332

5.  Identification of major histocompatibility complex class II-restricted antigens and epitopes of the Epstein-Barr virus by a novel bacterial expression cloning approach.

Authors:  Slavoljub Milosevic; Uta Behrends; Dinesh Adhikary; Josef Mautner
Journal:  J Virol       Date:  2006-11       Impact factor: 5.103

6.  Isolation of human MHC class II-restricted T cell receptors from the autologous T-cell repertoire with potent anti-leukaemic reactivity.

Authors:  Luise U Weigand; Xiaoling Liang; Sabine Schmied; Sabine Mall; Richard Klar; Oliver J Stötzer; Christoph Salat; Katharina Götze; Josef Mautner; Christian Peschel; Angela M Krackhardt
Journal:  Immunology       Date:  2012-11       Impact factor: 7.397

7.  A virus-like particle-based Epstein-Barr virus vaccine.

Authors:  Romana Ruiss; Simon Jochum; Gerhard Wanner; Gilbert Reisbach; Wolfgang Hammerschmidt; Reinhard Zeidler
Journal:  J Virol       Date:  2011-10-12       Impact factor: 5.103

8.  Epstein-Barr viruses that express a CD21 antibody provide evidence that gp350's functions extend beyond B-cell surface binding.

Authors:  Clemens Busse; Regina Feederle; Martina Schnölzer; Uta Behrends; Josef Mautner; Henri-Jacques Delecluse
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

9.  Standardized and highly efficient expansion of Epstein-Barr virus-specific CD4+ T cells by using virus-like particles.

Authors:  Dinesh Adhikary; Uta Behrends; Regina Feederle; Henri-Jacques Delecluse; Josef Mautner
Journal:  J Virol       Date:  2008-02-13       Impact factor: 5.103

10.  Functional analysis and molecular characterization of spontaneously outgrown human lymphoblastoid cell lines.

Authors:  Toralf Bernig; Nicole Richter; Ines Volkmer; Martin S Staege
Journal:  Mol Biol Rep       Date:  2014-07-19       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.